Bristol-Myers ends development agreement with Merck

Article

Bristol-Myers Squibb and Merck have agreed to end their collaborative development of the investigational oral diabetes drug Pargluva (muraglitazar). Under the termination agreement, all rights to muraglitazar were returned to Bristol-Myers effective Dec. 21, 2005. The agreement also returns to Bristol-Myers the rights to a backup compound to muraglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor. Bristol-Myers did indicate that it would continue discussions with the FDA about the drug.

Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.